Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
35570988
Public Release Type:
Journal
Publication Year: 2022
DOI:
https://doi.org/10.1016/j.ekir.2022.02.009
Authors:
Zhou Xiaolei, Davenport Eric, Ouyang John, Hoke Molly E., Garbinsky Diana, Agarwal Indra, Krasa Holly B., Oberdhan Dorothee
Request IDs:
21540
Studies:
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
In 1- and 3-year randomized trials, tolvaptan slowed kidney function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. The 3-year trial also evaluated effects on total kidney volume (TKV); slowing of TKV growth was demonstrated. Subjects were followed in open-label extension trials. To characterize longer-term effects of treatment, an analysis was conducted comparing tolvaptan-treated subjects with subjects from standard of care (SOC) ADPKD studies without tolvaptan.
